Fresenius continues steady growth:
This article was originally published in Clinica
First-quarter turnover at Fresenius rose 13% to DM 534 million ($368 million), almost entirely due to foreign business. Revenue breakdown by division was: dialysis technology 56%; pharmaceuticals 33%; critical care and diagnostics 7%; and project business 4%. Net income was DM 15 million, up 19% compared with 1994. Fresenius expects total sales in 1995 to rise 10%.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.